相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective
Thomas Webb et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)
Targeting EZH2 for cancer therapy: From current progress to novel strategies
Jia Zeng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas
Bin Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2
Zhihao Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma
Yalin Tu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors
Hualong He et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer
M. Cynthia Martin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
PRC2 functions in development and congenital disorders
Orla Deevy et al.
DEVELOPMENT (2019)
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
Pei-Pei Kung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas
W Harb et al.
ANNALS OF ONCOLOGY (2018)
Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays
Yunlong Wu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat
Kevin W. Kuntz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance
Alexei Brooun et al.
NATURE COMMUNICATIONS (2016)
Discovery, design, and synthesis of indole-based EZH2 inhibitors
Victor S. Gehling et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
SAH derived potent and selective EZH2 inhibitors
Pei-Pei Kung et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Targeting histone lysine methylation in cancer
John McGrath et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors
Jimin Woo et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Regulation and Role of EZH2 in Cancer
Hirohito Yamaguchi et al.
CANCER RESEARCH AND TREATMENT (2014)
Chromatin proteins and modifications as drug targets
Kristian Helin et al.
NATURE (2013)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
A687V EZH2 is a gain-of-function mutation found in lymphoma patients
Christina R. Majer et al.
FEBS LETTERS (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
Michael T. McCabe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
Tim J. Wigle et al.
FEBS LETTERS (2011)
The Polycomb complex PRC2 and its mark in life
Raphael Margueron et al.
NATURE (2011)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
Christopher J. Sneeringer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Protein methyltransferases as a target class for drug discovery
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Jeffrey A. Simon et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites
B Czermin et al.
CELL (2002)
Histone methyltransferase activity of a Drosophila polycomb group repressor complex
J Müller et al.
CELL (2002)
分享论文
